1 ticket wins $12.3 million Toto jackpot draw
SINGAPORE - A single ticket has won the $12.3 million Toto jackpot on June 19 after the past three draws saw no winners.
The winning numbers were 1, 10, 37, 40, 45, 47. The additional number was 19.
The winning ticket was bought at the NTUC FairPrice at Yew Tee Point under the QuickPick System 7 Entry. It is not known if the ticket belonged to an individual or was shared among several people.
Meanwhile, 13 tickets won the Category 2 prize, which had a share amount of $108,637.
Earlier, the Singapore Pools' website showed that the prize money for the Group 1 category had snowballed from almost $1.3 million on June 9 to $2.9 million on June 12.
The last draw on June 16, which had a prize money of $5.6 million, had again yielded no winner.
The Group 1 prize amount will snowball only up to the fourth draw. Thereafter, the amount will be shared among the winners in Group 2.
The last Toto draw that had a prize sum of over $10 million was on April 28, with two winning tickets sharing $12.9 million.
In 2024, a single ticket won $13.1 million. The record was set on May 9 that year.
The latest draw results are available on the Singapore Pools website.
Source: The Straits Times © SPH Media Limited. Permission required for reproduction
Discover how to enjoy other premium articles here
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Investors in Engtex Group Berhad (KLSE:ENGTEX) have seen respectable returns of 68% over the past five years
When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking involves risks (and requires diversification) it can also provide excess returns. To wit, the Engtex Group Berhad share price has climbed 58% in five years, easily topping the market return of 6.2% (ignoring dividends). So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. While Engtex Group Berhad made a small profit, in the last year, we think that the market is probably more focussed on the top line growth at the moment. Generally speaking, we'd consider a stock like this alongside loss-making companies, simply because the quantum of the profit is so low. It would be hard to believe in a more profitable future without growing revenues. In the last 5 years Engtex Group Berhad saw its revenue grow at 8.5% per year. That's a pretty good long term growth rate. While the share price has beat the market, compounding at 10% yearly, over five years, there's certainly some potential that the market hasn't fully considered the growth track record. The key question is whether revenue growth will slow down, and if so, how quickly. There's no doubt that it can be difficult to value pre-profit companies. You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image). It's probably worth noting that the CEO is paid less than the median at similar sized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. So it makes a lot of sense to check out what analysts think Engtex Group Berhad will earn in the future (free profit forecasts). When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. We note that for Engtex Group Berhad the TSR over the last 5 years was 68%, which is better than the share price return mentioned above. And there's no prize for guessing that the dividend payments largely explain the divergence! While the broader market lost about 6.9% in the twelve months, Engtex Group Berhad shareholders did even worse, losing 12% (even including dividends). However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. On the bright side, long term shareholders have made money, with a gain of 11% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 4 warning signs with Engtex Group Berhad (at least 1 which shouldn't be ignored) , and understanding them should be part of your investment process. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Malaysian exchanges. — Investing narratives with Fair Values Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor Fair Value Estimated: A$2.42 · 0.1% Overvalued Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor Fair Value Estimated: €78.41 · 0.1% Overvalued Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor Fair Value Estimated: $325.55 · 0.6% Undervalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
SURGLASSES Launches the World's First AI Anatomy Table
Asclepius AI Table sets a new benchmark for intelligent, hands-on medical learning. TAIPEI, June 19, 2025 /PRNewswire/ -- Surglasses Inc. today announced the launch of the Asclepius AI Table, the world's first anatomy table with fully integrated AI instruction — a groundbreaking device that brings real-time intelligence and immersive interaction into medical and veterinary education. Unlike traditional systems that rely on external software or passive content, the Asclepius AI Table is a self-contained, AI-enhanced teaching platform. Two built-in digital instructors respond to voice and text in real time, offering guided instruction, anatomical explanations, and adaptive learning based on user input. The system is ready to use out of the box, requiring no technical setup or training, making it ideal for classrooms, labs, and interactive demonstrations. The table features eight deeply integrated modules designed to meet the diverse demands of modern medical and veterinary curricula. Students can freely explore high-resolution 3D virtual cadavers, perform open-ended digital dissection, and examine body structures from any angle. For radiological learning, the table enables ultra-fast 3D reconstruction and visualization of CT scans through a built-in DICOM viewer, with multiple rendering presets for efficient analysis. In the field of pathology, the Histopathology Explorer launches in seconds and includes a large collection of ultra-HD slides, while also supporting custom slide uploads. Movement and biomechanics are covered through the Kinesiology Module, which presents dozens of animated human motion models for understanding joint mechanics and musculoskeletal interactions. Additional tools include CTRender, a powerful engine for importing and manipulating DICOM files; a real-time ultrasound simulator that supports procedural training using clinical data; and a robust veterinary anatomy library with anatomical models for a wide range of species — supporting both human and animal education in a unified environment. The Embryology Timeline rounds out the system, offering a vivid 3D visualization of human development from fertilization to birth — helping students connect macro-level anatomy with developmental biology in a way that textbooks alone cannot achieve. Across all modules, the embedded AI instructors serve as constant companions: answering questions, guiding exploration, and supporting instructors and students alike with precision and immediacy. "The Asclepius AI Table is the first of its kind — an anatomy table that doesn't just show, it teaches," said Dr. Min-Liang Wang, founder and CEO of Surglasses Inc. "By embedding intelligent guidance directly into the table, we're transforming how anatomy and clinical science are taught — making learning faster, deeper, and more intuitive." Now Available for Global Distribution Already generating strong interest from medical schools, teaching hospitals, and veterinary institutions, the Asclepius AI Table is now available worldwide. Surglasses welcomes demo requests, academic partnerships, and distribution inquiries. Media ContactMarketing info@ nina@ About Surglasses Inc. Surglasses Inc. develops next-generation solutions for medical training and surgical navigation. Its flagship technologies — including the Caduceus S AR spinal navigation system and the Asclepius AI Table — are redefining how healthcare professionals learn, plan, and perform with greater confidence and clarity. View original content to download multimedia: SOURCE SURGLASSES
Yahoo
32 minutes ago
- Yahoo
Celcomdigi Berhad (KLSE:CDB) shareholders have earned a 10% CAGR over the last three years
By buying an index fund, you can roughly match the market return with ease. But if you pick the right individual stocks, you could make more than that. For example, Celcomdigi Berhad (KLSE:CDB) shareholders have seen the share price rise 20% over three years, well in excess of the market return (8.3%, not including dividends). On the other hand, the returns haven't been quite so good recently, with shareholders up just 7.1%, including dividends. So let's assess the underlying fundamentals over the last 3 years and see if they've moved in lock-step with shareholder returns. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). Over the last three years, Celcomdigi Berhad failed to grow earnings per share, which fell 6.8% (annualized). So we doubt that the market is looking to EPS for its main judge of the company's value. Since the change in EPS doesn't seem to correlate with the change in share price, it's worth taking a look at other metrics. It may well be that Celcomdigi Berhad revenue growth rate of 27% over three years has convinced shareholders to believe in a brighter future. In that case, the company may be sacrificing current earnings per share to drive growth, and maybe shareholder's faith in better days ahead will be rewarded. You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values). Celcomdigi Berhad is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. Given we have quite a good number of analyst forecasts, it might be well worth checking out this free chart depicting consensus estimates. It is important to consider the total shareholder return, as well as the share price return, for any given stock. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. As it happens, Celcomdigi Berhad's TSR for the last 3 years was 33%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments! It's nice to see that Celcomdigi Berhad shareholders have received a total shareholder return of 7.1% over the last year. Of course, that includes the dividend. That's better than the annualised return of 1.7% over half a decade, implying that the company is doing better recently. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 2 warning signs for Celcomdigi Berhad you should be aware of, and 1 of them is significant. If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Malaysian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
